The “don't eat me” signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The “don't eat me” signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma
Authors
Keywords
-
Journal
OncoImmunology
Volume 7, Issue 1, Pages e1373235
Publisher
Informa UK Limited
Online
2017-09-05
DOI
10.1080/2162402x.2017.1373235
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma
- (2017) Stephanie M. McGregor et al. HUMAN PATHOLOGY
- Introduction to checkpoint inhibitors and cancer immunotherapy
- (2017) Arlene H. Sharpe IMMUNOLOGICAL REVIEWS
- Scientific Advances in Thoracic Oncology 2016
- (2017) Ross A. Soo et al. Journal of Thoracic Oncology
- Immune checkpoint inhibitors in malignant pleural mesothelioma
- (2017) Giovanni Luca Ceresoli et al. LANCET ONCOLOGY
- Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
- (2017) Evan W Alley et al. LANCET ONCOLOGY
- BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas
- (2016) Harry C. Hwang et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line
- (2015) Walter Blum et al. IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL
- Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology
- (2015) Juliana Andrici et al. MODERN PATHOLOGY
- The Worldwide Pandemic of Asbestos-Related Diseases
- (2013) Leslie Stayner et al. Annual Review of Public Health
- Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers
- (2013) Douglas W Henderson et al. JOURNAL OF CLINICAL PATHOLOGY
- Surgery in Mesothelioma – Where Do We Go after MARS?
- (2013) Birgitta I. Hiddinga et al. Journal of Thoracic Oncology
- Next-generation tissue microarray (ngTMA) increases the quality of biomarker studies: an example using CD3, CD8, and CD45RO in the tumor microenvironment of six different solid tumor types
- (2013) Inti Zlobec et al. Journal of Translational Medicine
- The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implications
- (2012) Mark P Chao et al. CURRENT OPINION IN IMMUNOLOGY
- Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma
- (2012) B. Edris et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
- (2012) S. B. Willingham et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pleural mesothelioma side populations have a precursor phenotype
- (2011) Claudia Frei et al. CARCINOGENESIS
- The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
- (2011) Matthew Bott et al. NATURE GENETICS
- In vitro and in vivo characterization of highly purified Human Mesothelioma derived cells
- (2010) Alice Melotti et al. BMC CANCER
- The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions
- (2010) Farnaz Hasteh et al. CANCER CYTOPATHOLOGY
- Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia
- (2010) Mark P. Chao et al. CANCER RESEARCH
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
- (2010) Mark P. Chao et al. CELL
- Fluorescence In Situ Hybridization in the Definitive Diagnosis of Malignant Mesothelioma in Effusion Cytology
- (2010) Spasenija Savic et al. CHEST
- Activation of CD47 receptors causes proliferation of human astrocytoma but not normal astrocytes via an Akt-dependent pathway
- (2010) Emilie Sick et al. GLIA
- Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47
- (2010) M. P. Chao et al. Science Translational Medicine
- Usefulness of EMA, GLUT-1, and XIAP for the Cytologic Diagnosis of Malignant Mesothelioma in Body Cavity Fluids
- (2009) Jian Shen et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
- (2009) Siddhartha Jaiswal et al. CELL
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
- (2009) Ravindra Majeti et al. CELL
- Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cells
- (2008) Richard K. Tsai et al. JOURNAL OF CELL BIOLOGY
- Functional inactivation of NF2/merlin in human mesothelioma
- (2008) Claudio Thurneysen et al. LUNG CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started